Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00464061 · ClinicalTrials.gov registry record · Phase 3
Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,847
- Enrollment target
NCT00464061 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 1,847 participants.
The verdict
NCT00464061, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,847 participants
- Enrollment target
Study Summary
The purpose of this study is to assess efficacy and safety of volinanserin in the population of patients complaining of sleep maintenance insomnia. The objective of the substudy is to assess glycemic control in the subgroup of patients with type II diabetes mellitus.
Interventions
- DRUG Placebo
- DRUG Volinanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,847 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00464061
The ClinicalTrials.gov registry entry for NCT00464061 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,847 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00464061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00464061 about?
NCT00464061 is a clinical study titled "Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus". The purpose of this study is to assess efficacy and safety of volinanserin in the population of patients complaining of sleep maintenance insomnia. The objective of the substudy is to assess glycemic control in the subgroup of patients with type II diabetes mellitus.
What is the current status of trial NCT00464061?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,847 participants. The study started on 2007-04. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00464061?
The interventions under investigation include: Placebo (DRUG), Volinanserin (DRUG).
Who is sponsoring clinical trial NCT00464061?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.